To study the difference in the survival between the G-st-π negative [G-st-π (-)] and G-st-π positive [G-st-π (+)] in chemotherapy patients with inoperable NSCLC. Our hypothesis was that the G-st-π(+) patients will not response to chemotherapy.
24 patients with NSCLC stage IIIb were studied. All patients were submitted in 3 cycles of chemotherapy with Ifosfamide, Cis-platin and Vinblastine. After the 3 first cycles the patients were reevaluated and characterized as complete responders (CR), partial responders (PR), and non responders (NR) according to international standards. The expression of G-st-π was determined with semiquantitative immunohistochemical method in cytological specimens of the patients which were obtained by fiberoptic bronchoscopy. The NR were switched to palliative care . The 24 months survival was determined for all patients.
G-st-π(-) patients total 13, CR and PR patients 12(92.3%), NR patient 1 (7.7%). G-st-π(+) patients total 11, CR and PR patients 4(36.4%), NR patients 7 (63.6%)p value (Fisher’s exact test) 0.008G-st-π(-): 13 patients mean survival time 19 monthsG-st-π(+):11 patients mean survival time 9 monthsp value 0.0022NR 8 patients, mean survival time 5.95 monthsPR 11 patients, mean survival time 15.63 monthsCR 5 patients, mean survival time 21.84 monthsp value <0.0001CONCLUSIONS: 1)The expression of G-st-π could be used as a prognostic factor for the response to chemotherapy2) The 24 months survival time presents a statistically significant difference between G-st-π(-) and G-st-π(+) patients3) The survival time for the NR patients is comparable with this of the patients who are submitted to the best support treatment.CLINICAL APPLICATION: The use of prognostic factors for the response to chemotherapy in clinical practice could diminish the cost of the antineoplasmatic treatment, and improve the quality of life for those patients that would not respond to chemotherapy.
G.S. Vlachogeorgos, None.